Recordati Stock - Thursday technical picture and volatility snapshot
18.06.2026 - 16:21:41 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 14:15 CET. Details in the imprint.
Recordati (IT0003828271) enters Thursday without any newly reported corporate announcements from its investor-relations or top-tier newswires. Against this backdrop, the focus for investors is on the latest chart levels and volatility signals for the Milan-listed pharmaceutical group.
Background and data on Recordati stock
Key figures, past coverage and additional context on Recordati’s shares can be found in the dedicated topic section and on the company’s investor-relations pages.
What recent prices indicate
For Recordati, the most recently verifiable closing indication is a quote of EUR 50.60 per share, unchanged on 06/17/2026, according to a technical snapshot compiled by Traders Union for the REC/EUR line.
This external technical overview classifies the short-term signal mix as leaning toward "sell" on several intraday indicators, while the flat closing level underlines muted immediate momentum rather than a sharp directional move.
Thursday’s chart and volatility focus
With no new fundamental headlines, attention on Thursday centers on how Recordati’s shares behave around recent trading ranges and whether volatility remains subdued around the EUR 50 mark. Short-term traders are watching if the prior close at EUR 50.60 holds as a nearby reference level.
From a descriptive standpoint, the latest neutral session suggests that, at least for now, Recordati’s chart is shaped more by broader sector sentiment than by company-specific catalysts, in line with the lack of fresh filings or ad-hoc news.
The business behind the ticker
Recordati is a long-established Italian pharmaceutical group focusing on specialty and rare-disease medicines, including treatments in cardiovascular, urology and metabolic disorders, and it is a constituent of the FTSE MIB index on Borsa Italiana.
The company has expanded from its historical Italian base into a multi-country European footprint and selected international markets, aiming for steady growth in niche indications rather than broad primary-care mass markets, according to its positioning as outlined on the investor-relations site.
How the company makes money
Commercially, Recordati generates revenue from a portfolio of prescription drugs in specialty therapeutic areas, complemented by selected over-the-counter brands, with a strategic emphasis on acquiring or in-licensing niche products that can be scaled across its distribution network.
On balance, this business model targets relatively resilient demand patterns and pricing power in rare and specialty conditions, where competition is often limited and medical need is clearly defined.
Where the stock trades today
Recordati shares trade on Borsa Italiana in Milan; at the time of the latest reliable technical snapshot, the last indicated close was EUR 50.60 on 06/17/2026, while a fully up-to-date live quote for 06/18/2026 was not independently verifiable.
Key facts on Recordati stock
- Company: Recordati S.p.A.
- ISIN: IT0003828271
- Venue: Borsa Italiana (Milan)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: FTSE MIB
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
